You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
廣生堂(300436.SZ):獲得抗新型冠狀病毒藥物臨牀試驗倫理委員會批件
格隆匯 02-12 16:58

格隆匯2月12日丨廣生堂(300436.SZ)公佈,公司高度關注新型冠狀病毒疫情,正全力推進抗新型冠狀病毒藥物的研發工作,詳見《關於開展抗2019-nCoV藥物研發的公告》。

近日,由中華醫學會感染病學分會副主任委員、同濟醫院感染科主任、同濟醫院感染性疾病研究所所長寧琴教授作為主要研究者(PI)發起的“G1治療中重度新型冠狀病毒感染肺炎的小樣本量預試驗(GST-G1)”已獲得武漢疫情核心區華中科技大學同濟醫學院附屬同濟醫院倫理委員會出具的倫理批件,同意開展“G1治療中重度新型冠狀病毒感染肺炎的小樣本量預試驗”臨牀研究,現正有序推進中。

上述藥物的臨牀試驗結果及後續能否獲批用於治療新型冠狀病毒肺炎尚存在諸多不確定。公司將按照相關規定履行信息披露義務,敬請廣大投資者注意投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account